Not everyone taking a GLP-1 medicine will experience the same benefits
Like other GLP-1 based medications, stopping treatment can lead to a return of appetite and some weight regain if no other supports are in place
Similar content being viewed by others Background Glucagon-like peptide-1 (GLP-1) receptor agonists, exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide, are among the recent subcutaneous treatment options that provide better glycemic improvement and weight loss in patients with type 2 diabetes according to the current guidelines [1, 2]
Mol Metab 2021;49:101181
Some people may feel full quickly, feel bloated after eating, or notice more burping than usual
Gastroparesis (stomach paralysis), which has been linked to Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, and Trulicity, causes constant and severe nausea and vomiting, abdominal pain, severe dehydration, acid reflux, malnutrition, and weight loss